ArticleMikrochimica acta2026
Supramolecular co-assembly of platycodin-d-loaded iron nanocomposite enhances hepatocellular carcinoma immunotherapy with synergistic ferroptosis-photo-chemotherapy.
Article in Mikrochimica acta, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
Immune checkpoint blockades (ICBs) have potential application in cancer therapy. The lack of adaptive resistance and immunogenicity in cells substantially restricts their preclinical efficiency. Immunogenic cell death (ICD), a form of regulated cell death, plays a crucial role in activating the adaptive immune response. A co-assembled metal coordination nanocomposite (PIF NCs) that improves cancer immunotherapy by promoting ICD via ferroptosis-photochemotherapy induction is developed. The PIF NCs demonstrated exceptional stability and biocompatibility and exhibited effective photodynamic therapy and photothermal therapy effects. PIF NCs disrupt the redox equilibrium and trigger ferroptosis by depleting glutathione (GSH), downregulating glutathione peroxidase 4 (GPX4) and solute carrier family 7 member 11 (SLC7A11), and increasing the production of lipid peroxides (LPO). PIF NCs initiate the ICD cascade, thereby augmenting tumor immunogenicity. In a Hep3B tumor model, combined treatment with PIF NCs and anti-PD-L1 exhibited substantial inhibitory efficacy and induced a prolonged immunological memory response. This synergistic treatment of multimodal therapy can potentially be used in the treatment of hepatocellular carcinoma.
Indexed as
Identifiers
42133129What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.